Search

Memorial Sloan Kettering researchers have developed a powerful new way to study human disease using stem cells whose genomes can be manipulated at will.

… Thursday, August 7, 2014 Summary Memorial Sloan Kettering researchers have developed a powerful new way to study human disease using stem cells whose genomes can be manipulated at will. Memorial Sloan Kettering researchers have pioneered a new method to study complex genetic conditions including cancers

Our findings indicate that surgical site infections can be reduced effectively over the long term with a hospital-wide implementation of multidisciplinary best practices.

… Thursday, December 13, 2018 Implementation of a multidisciplinary care bundle composed of 13 perioperative components has significantly decreased the rate of surgical site infections (SSIs) among patients undergoing colorectal cancer surgery at Memorial Sloan Kettering Cancer Center, according to our

The Specialized Programs of Research Excellence (SPORE) grant will fund efforts focusing on the development of new treatments.

… Tuesday, September 7, 2021 Memorial Sloan Kettering Cancer Center has received a major grant from the US National Institutes of Health (NIH) to conduct research related to leukemia . It is the sixth grant of this type to be received by MSK investigators. It is referred to as a SPORE grant, for Specialized

Pediatric surgeon J. Ted Gerstle, MD, FACS, FRCS, has been named the new Chief of the Pediatric Surgery Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK).

… Thursday, July 12, 2018 Pediatric surgeon J. Ted Gerstle, MD, FACS, FRCS , has been named the new Chief of the Pediatric Surgery Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK). An accomplished physician and leader, Dr. Gerstle most recently served as Director of

The immunotherapy drug nivolumab is now approved for patients whose Hodgkin lymphoma has failed other treatments.

… Thursday, May 19, 2016 https://www.youtube.com/watch?v=lrB1gjztQSk The immunotherapy drug nivolumab is giving hope to Hodgkin lymphoma patients like Ariella after standard treatments don’t work. Video courtesy Cancer Research Institute. Summary Patients with Hodgkin lymphoma whose disease returns after

Chief of the Melanoma Service Michael Postow, MD, Medical Oncologist Nitya Raj, MD, and Assistant Attending Triparna Sen, PhD were included on this year’s list.

… Thursday, October 15, 2020 Memorial Sloan Kettering (MSK) is proud to announce that Chief of the Melanoma Service https://www.mskcc.org/cancer-care/doctors/michael-postow Michael Postow, MD , Medical Oncologist  Nitya Raj, MD , and Assistant Attending Triparna Sen, PhD, are included in the 40 Under 40

New research focuses on clonal hematopoiesis, an age-related blood condition that increases the risk of blood cancer.

… Monday, October 26, 2020 Summary MSK investigators uncover new findings about the relationship between clonal hematopoiesis in cancer patients and the risk of later developing a treatment-related blood cancer. In recent years, improvements in cancer therapy have led to a significant increase in cancer

Couldn’t be at ASCO this year? Read highlights from the first half of the meeting.

… Monday, June 6, 2016 Summary Among the highlights presented at this year’s American Society of Clinical Oncology annual meeting were advances in targeted therapy for small cell lung cancer, immunotherapy for non-small cell lung cancer, and insights into the biology of bladder cancer immunotherapy responders

After years of planning and anticipation, the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is scheduled to open in January 2020.

… Friday, December 6, 2019 After years of planning and anticipation, the  David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is scheduled to open in January 2020.   Located off York Avenue on 74th Street, the David H. Koch Center for Cancer Care at Memorial Sloan Kettering is

Westchester Medical Center today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center, whose staff will provide outpatient cancer care and infusion services.

… Wednesday, February 13, 2013 Westchester Medical Center (WMC) today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center (MSKCC), whose staff will provide outpatient cancer care and infusion services.